Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X about a paper by Andrew Kennedy et al. published in Radiation Oncology:
“A new publication shows SBRT is more cost-effective, with a greater improvement in quality of life than surgery for stage I NSCLC. As usual, there are caveats with the analyses.”
Title: A prospective outcomes and cost-effective analysis of surgery compared to stereotactic body radiation therapy for stage I non-small cell lung cancer
Authors: Andrew Kennedy, Shanna A. Arnold Egloff, Casey Martin, Denis Gilmore, Susan Garwood, Tammy Baxter, David Spigel, Melissa Johnson, David Randolph II, Casey Chollet-Lipscomb, Laurie Cuttino, Eleanor Osborne, Jenifer Marks, Pratik Doshi, Meredith Mattlin, Richard Geer, Dax Kurbegov, Howard Burris III
You can read the Full Article in Radiation Oncology.
More posts featuring Drew Moghanaki.